Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Kyomarc
Treatment of breast cancer, non-small cell lung cancer, renal cell cancer, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, platinum-sensitive epithelial ovarian, fallopian tube or primary
Lytenava
Lytenava is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
View on EMA